HOME >> BIOLOGY >> NEWS
Max Planck researchers make a breakthrough in plant stem cell research

Totipotent stem cells allow plants to build new organs throughout their whole life. But it has been unclear how hormones and genetic factors work together to prevent plants from having growth that is either stunted, or uncontrolled and tumor-like. Scientists from the Max Planck Institute for Developmental Biology have now uncovered a feedback mechanism, involving a growth-enhancing hormone and a regulatory protein, which controls the number of stem cells the plant produces. (Nature, December 22, 2005). The results are of great importance for all of stem cell research.

All above ground parts of a plant - leaves, stem, flowers, and seeds - ultimately are derived from cells of a small tissue at the tip of the shoot. Biologists call this tissue the "apical meristem", and it contains totipotent stem cells that are active throughout the life of the plant. Unlike the stem cells of animals, which can only produce specific kinds of tissue after the animal is past its embryonic stage, plant stem cells remain their totipotency and, therefore plants can continue growing over many years, developing new organs.

But this ability comes at a price. If the number of meristematic stem cells increases too quickly, then there could be uncontrolled growth, similar to cancer. On the other hand, if the stem cell pool shrinks too quickly, the plant could have stunted growth. In order to stay alive and reproduce, the plant needs to find the right balance in the number of its stem cells. Two regulatory mechanisms were found to be important for this process. The first involves growth-promoting hormones like auxin and cytokinin, known already for more than half a century. The second involves genetic factors, which were discovered at the University of Tübingen, Germany about a decade ago. Here it was shown that a gene called WUSCHEL has a key influence on how many cells in the apical meristem actually stay stem cells. However, until now, it was unclear how hormones and regulatory
'"/>

Contact: Dr. Jan Lohmann
jan.lohmann@tuebingen.mpg.de
497-071-601-1405
Max-Planck-Gesellschaft
22-Dec-2005


Page: 1 2 3

Related biology news :

1. 454 Life Sciences and Max Planck publish sequence of one million base pairs
2. Max Planck researchers win part of Descartes Research Prize 2005
3. Global commitment of Max Planck researchers
4. Four Max Planck Partner Groups starting in India
5. First Max Planck Partner Institute in China
6. Innovative tagging technique may help researchers better protect fish stocks
7. Penn researchers discover how key protein stops inflammation
8. ASU researchers partner with UOP to make biofuel for military jets a reality
9. Einstein researchers prototype vaccine could provide improved protection against tuberculosis
10. Penn researchers discover pathway that eliminates genetic defects in red blood cells
11. U-M researchers find family of on switches that cause prostate cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/10/2017)... Research and Markets has announced the addition ... and Commercial Aspects" to their offering. ... Biomarkers play an ... for selection of treatment as well for monitoring the results. ... in modern medicine. Biochip/microarray technologies and next generation sequencing are ...
(Date:2/8/2017)... NEW YORK , Feb. 7, 2017 Report ... ... and should reach $11.4 billion by 2021, growing at a ... Report Includes - An overview of the global markets for ... from 2015, estimates for 2016, and projections of compound annual ...
(Date:2/7/2017)... Feb. 7, 2017 Zimmer Biomet Holdings, Inc. ... healthcare, will present at the LEERINK Partners 6th Annual ... Hotel on Wednesday, February 15, 2017 at 10 a.m. ... the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  ... conference via Zimmer Biomet,s Investor Relations website at ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... 2017   Capricor Therapeutics, Inc. (NASDAQ: ... developing first-in-class biological therapies for cardiac and other ... to terminate its license agreement with the Mayo ... Cenderitide. "Our decision to return these ... our efforts to advance our core cell and ...
(Date:2/16/2017)... , Feb. 16, 2017  Champions Oncology, Inc. ... the development and sale of advanced technology solutions and ... drugs, today announced the addition of new cohorts of ... These new models will expand Champions, product line in ... and neck cancer, AML, and non-small cell lung cancer ...
(Date:2/16/2017)... WEST LAFAYETTE, Indiana (PRWEB) , ... ... ... a division of Albany Molecular Research Inc. has further extended its industry ... sector. This service offers state-of-the-art cGMP techniques and methods for the ...
(Date:2/15/2017)... Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial ... full year ended December 31, 2016. ... we continued to demonstrate strong growth in our ... said Mihael H. Polymeropoulos, M.D., Vanda,s President and ... 2017 milestones underscores Vanda,s commitment to bringing important ...
Breaking Biology Technology:
Cached News: